Drug Database
AD

AD-214 (AD 214, Addpharma / AD214, Addpharma)

✓ Approved

Addpharma · 小分子 · 小分子

什么是 AD-214?

AD-214 是一种小分子,由Addpharma研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名AD 214, Addpharma, AD214, Addpharma
公司Addpharma
药物类别小分子
给药途径Oral (PO)
状态Approved

治疗适应症

AD-214 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersGastrooesophageal reflux disease✓ Approved

相关研究文献

PubMedMicrobiology resource announcements2026-11-17

Draft genome sequence of Salmonella enterica subsp. enterica serovar Emek SBI_US12_TA_BD isolated from broiler chicken in Bangladesh.

Anzum Tahrima T, Hossen Tamanna T, Sahib Md Safayat MS, Jahan Esrat E et al.

Salmonella enterica is a rod-shaped, Gram-negative bacterium that belongs to the Enterobacteriaceae family. Herein, we report the 4,948,228 bp genome (52.09% G + C) with 214× genome coverage of Salmonella enterica SBI_US12_TA_BD, containing a total of 4,784 CDSs, 43 tRNA, and 3 rRNA genes.

PMID 43042795
阅读全文 →
PubMedFrontiers in microbiology2026-11-17

Sex-specific alterations in gut microbiome composition in patients with Alzheimer's disease.

Lin Xiu-Qin XQ, Hua Hong-Hao HH, Zhang Xin-Yuan XY, Lv Dan-Ping DP et al.

The microbiota-gut-brain axis plays a significant role in the pathology of Alzheimer's disease (AD). However, alterations in the gut microbiome structure of AD patients and the sex-specific differences in signature microbial taxa remain inadequately characterized. A total of 100 participants were enrolled, including 60 in the AD case group. Gut microbiota was analyzed by 16S ribosomal RNA (16S rRNA) sequencing. Models incorporating disease group, sex, and a disease-sex interaction term were constructed to test whether sex modifies the effect of AD on gut microbiota α diversity. Stratified analyses were performed to compare α and β diversity between the AD and healthy control (HC) groups in male and female populations, respectively. Differential signature taxa between the two groups were explored using linear discriminant analysis effect size (LEfSe) and random forest analysis. A total of 36,168 amplicon sequence variants (ASVs) were obtained, with 1,917 ASVs shared between the AD and HC groups. No interaction effect between AD and sex on gut microbiota diversity was observed (interaction p-FDR > 0.05). In the sex-stratified analysis, gut microbiota evenness indices (Simpson, Shannon, and Pielou's indices) were lower in AD patients than in controls among both male and female populations (p-FDR < 0.05), whereas species richness (Chao1 and Observed_species) was significantly reduced only in female AD patients (p-FDR < 0.05). Significant differences in gut microbiota beta diversity were observed between the AD and control groups in both the male population (Stress = 0.213) and the female population (Stress = 0.253) (ANOSIM; males: R = 0.365, p = 0.001; females: R = 0.133, p = 0.001). In the male population, 11 signature taxa, including Bacilli, Lactobacillales, and Macellibacteroides, were significantly enriched in the AD group; in the female population, 12 signature taxa, including [Ruminococcus], Alistipes, and Rikenellaceae, were significantly enriched in the AD group. In the overall prediction of the random forest model distinguishing the AD group from the control group, the accuracy was 85.71% and 90.77% in the male and female populations, respectively, and the taxa contributing most to group classification were Pseudoramibacter_Eubacterium and Lachnospira, respectively (Gini importance = 0.059 for both). The gut microbiota of AD patients exhibits distinct, sex-specific signature taxa.

PMID 43041466
阅读全文 →
PubMedNature communications2026-11-17

APOE ε4 carriership status enhances age-related changes in Alzheimer's disease plasma biomarkers concentrations.

Rousset Rebecca Z RZ, den Braber Anouk A, Bongers Bram B, Boonkamp Lynn L et al.

Alzheimer's disease (AD) plasma biomarkers are cost-effective tools to detect early stage amyloid pathology. We investigated how interactions between AD genetic risk (apolipoprotein E (APOE) ε4, AD polygenic risk score (excluding APOE; PRSAD)), age, and sex affected AD plasma biomarkers concentrations in a population-based cohort. We included 5913 participants from the Netherlands Twin Register age 30 - 80 (64.1% females, 29.8% ε4 carriers) and measured plasma phosphorylated-tau-217 (p-tau217), amyloid-β-42/40 (Aβ-42/40), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP). We showed that the PRSAD did not associate with biomarker concentrations over age. In ε4 carriers, decreases in Aβ-42/40 became steeper after age 50, and increases in p-tau217 and GFAP became steeper after age 55 and 60 compared to non-carriers, respectively. Analyses in a separate longitudinal cohort (EMIF-AD) confirmed that p-tau217 concentration changes in ε4 carriers reflect AD pathology. These results highlight the potential of plasma biomarkers, especially p-tau217, for early detection of preclinical AD pathology.

PMID 43039924
阅读全文 →
PubMedDrug and chemical toxicology2026-11-17

Integrative computational and in-vitro evidence implicates BCL2-associated apoptotic signaling in acetyl tributyl citrate-induced microglial toxicity.

Zou Songsong S, Li Lei L, Xiang Wenjun W, Li Yanglei Y et al.

Acetyl tributyl citrate (ATBC), a synthetic plasticizer, exhibits neurotoxic potential. Microglia sustain brain homeostasis, and their apoptosis and dysfunction are key drivers of Alzheimer's disease (AD) pathogenesis. However, the mechanism connecting ATBC exposure to microglial impairment and AD susceptibility remains unclear. Here, we applied an integrative computational and in-vitro framework to investigate BCL2-centered apoptotic signaling mediating ATBC-induced microglial toxicity. We retrieved ATBC targets from five prediction databases and AD-related genes from GeneCards and OMIM, obtaining 380 overlapping genes. Five hub genes (SRC, TNF, EGFR, BCL2, and ESR1) were screened via four centrality algorithms. Functional enrichment highlighted neurodegenerative disease pathways and microglia-related apoptotic cascades. We built 127 machine-learning models using two AD GEO cohorts (GSE122603, GSE97760). The robust Lasso + XGBoost ensemble (training AUC = 0.994) identified BCL2, SRC, ESR1, and EGFR as predictive features, with SHAP analysis pinpointing BCL2 as the top contributor. Molecular docking predicted favorable ATBC-BCL2 binding (-5.363 kcal/mol), and 100 ns molecular dynamics simulations supported stable complex formation. In BV2 microglia, ATBC dose-dependently reduced cell viability (IC50 = 59.59 μM), downregulated BCL2 expression, and activated caspase-dependent apoptosis. Collectively, our integrated evidence indicates that BCL2-associated apoptotic signaling mediates ATBC-provoked microglial toxicity, suggesting a plausible mechanistic link between ATBC exposure and AD-related signatures. This study proposes a microglia-oriented mechanistic hypothesis for AD susceptibility and offers a multi-omics paradigm for plasticizer risk assessment.

PMID 43040848
阅读全文 →
PubMedASN neuro2026-11-17

TUBB2A as a Candidate Therapeutic Target for Alzheimer's Disease: Orotidine-Mediated Metabolic Mechanisms and Druggability.

Liang Liling L, Zhang Jingjing J, Zhang Ying Y

As the most prevalent neurodegenerative disorder, Alzheimer's disease (AD) poses a pressing need for novel therapeutic targets. This study was designed to address this gap by screening and validating druggable genetic targets nominally associated with AD through an integrative multi-omics approach. Mendelian randomization (MR) screened the druggable genome. GTEx eQTL data and differential expression analysis identified core candidates. SMR, GSMR, and cross-tissue eQTL validation assessed putative causal effects and cross-tissue generalizability. Single-cell RNA sequencing (scRNA-seq) dissected cell type-specific expression. Virtual knockout combined with cell-cell communication analysis elucidated regulatory mechanisms. Mediation analysis evaluated Cerebrospinal fluid (CSF) metabolite involvement, and molecular docking screened therapeutic agents. Genetically predicted TUBB2A expression was nominally associated with AD risk. Virtual knockout analysis revealed that TUBB2A deficiency induced significant upregulation of SLC1A3 and HIF3A, suggesting compensatory glutamate clearance and hypoxic stress responses. Nominal mediation analysis suggested that the CSF metabolite orotidine may be involved in the TUBB2A-AD association. Molecular docking revealed high binding affinity between Eribulin mesylate and TUBB2A. This study identifies TUBB2A as a priority candidate gene for further validation in AD, proposes a potential role for orotidine in TUBB2A-related AD susceptibility, and identifies eribulin mesylate as a potential therapeutic agent worthy of further investigation, thereby generating testable hypotheses for future mechanistic and therapeutic studies. susceptibility, and identifies eribulin mesylate as a potential therapeutic agent worthy of further investigation, thereby generating testable hypotheses for future mechanistic and therapeutic studies.

PMID 43042626
阅读全文 →
PubMedACS nano2026-11-17

Structure-Engineered Lipid-Mineral Nanoparticles for Ligand-Free Myeloid RNAi Delivery in Alzheimer's Disease.

Shi Kexin K, Zhang Chenyun C, Chen Yaoxing Y, Li Haixia H et al.

Peripheral myeloid cells are key regulators of systemic inflammation and promising targets for immune intervention in Alzheimer's disease (AD). However, selective in vivo small interfering RNA (siRNA) delivery to these cells remains challenging because conventional lipid nanoparticles often exhibit predominant hepatic accumulation and usually require ligand or antibody modification for immune-cell targeting. Here, we report a structure-engineered lipid-mineral nanoparticle platform, termed MCP, for ligand-free myeloid RNA interference (RNAi) delivery. MCP integrates a calcium phosphate mineral phase with a phosphatidic acid-enriched lipid interface, enabling efficient siRNA incorporation. The Ca2+-lipid cooperative architecture promoted macropinocytosis-dependent uptake and preferential siRNA delivery to peripheral myeloid cells in vivo, particularly Ly6Chigh monocytes and macrophages, with enhanced delivery under AD-associated inflammatory conditions. Systemic delivery of MCP carrying siRNA against triggering receptor expressed on myeloid cells 1 (TREM1) attenuated neuroinflammatory and neurodegenerative pathology in an AD mouse model, supporting peripheral myeloid reprogramming as a route to modulate central nervous system (CNS) disease progression. Notably, MCP also achieved efficient TREM1 silencing in AD patient-derived peripheral blood mononuclear cells (PBMCs) and restored TREM1 expression toward healthy-control levels. This work establishes a structure-driven, ligand-free lipid-mineral RNAi platform for peripheral immune intervention in AD.

PMID 43043232
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多AD-214